Umbilical cord blood transplantation: current practice and future innovations.
As a source of hematopoietic stem cells (HSCs), umbilical cord blood (UCB) has the advantages of speed of availability, tolerance of 1-2 antigen HLA mismatch, and a low incidence of severe GVHD. Thus, UCB represents a highly convenient HSC source that may significantly extend the HSC donor pool. UCB transplantation (UCBT) has become a standard practice in the treatment of pediatric malignancies. Now, UCBT is being investigated in adults using both conventional and non-myeloablative preparative regimens. As graft cell dose is the major factor determining hematopoietic recovery and survival in URD UCBT, methods to increase cell dose such as multiple-unit transplant and ex vivo expansion are being pursued. This review outlines the current status of UCBT with emphasis on current and future innovations.
Department of Medicine, Blood and Marrow Transplant Program of the University of Minnesota School of Medicine, University of Minnesota, MMC 480 UMHC, 420 Delaware Street, SE, Minneapolis, MN 55455, USA. barker014@tc.umn.edu
Juliet N
JN
Barker
John E
JE
Wagner
D036101:Cord Blood Stem Cell Transplantation / Q000379:methods* / Q000639:trends; D006648:Histocompatibility; D006801:Humans; D007107:Immune System / Q000502:physiology; D012038:Regeneration; D019172:Transplantation Conditioning